Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: mlkr who wrote (2642)	6/21/2010 12:22:05 PM
From: tuck	Read Replies (2) \| Respond to of 3661

Re: AFFY's drop . . . The pre-dialysis subgroup -- which was prospective -- showed a stat sig increase in cardiovascular events. The FDA barely let epogen and aranesp stay on the market when this sort of thing became an issue (now black boxed and selling less), so it's doubtful it would approve Hematide. Other options are out there for this large population. The stock would have cratered even harder but for some dim hope the FDA would give approval for the dialysis population. AFFY is a one drug stock, and the drug is likely dead. Probably safe to short bounces here. Cheers, Tuck